Sensyne Health: Well placed to accelerate its commercial plans

Sensyne Health PLC is a clinical artificial intelligence company operating a unique business model – a for-profit plc making a positive social impact, sharing the financial returns it makes with health systems.

The company applies clinical AI in the healthcare and life science industries.

In healthcare, Sensyne delivers remote patient monitoring and real time decision making systems for healthcare organizations and their patients.

In life sciences, Sensyne analyses large complex anonymized data sets to help life sciences companies accelerate the development of new medicines.

() has agreed a deal with OMNY Health that gives it access to more than 22mln de-identified patient records held by the US firm.

It effectively doubles the dataset Sensyne has access to.

The UK group is at the cutting edge of data analysis and is using AI and machine learning to interrogate and analyse ethically-source patient records for findings that could aid drug development and/or help its health service partners.

Sensyne North America president, Derek Baird, said: “This relationship has been forged on a mutual belief in the power of real-world data to support breakthrough insights and discoveries.

Sensyne Health PLC (AIM:SENS, FRA:DSH) said it could meet full-year expectations as trading picks up in the second half, adding the launch of the SENSIGHT platform is expected to have a significant impact on the efficiency of its activities.

The AI-focused group said it is confident of strong revenue growth over the full financial year, as there are over 25 opportunities in the pipeline with life science customers that have potential contract value that would top current market expectations.

Sensyne Health PLC (AIM:SENS, FRA:DSH) launched an AI-enabled global data analytics platform for the healthcare and life sciences sectors.

Called SENSIGHT, the platform uses data derived from around 10mln anonymised and de-identified patients accumulated from research partnerships with NHS Trusts and US health systems.

Sensyne PLC’s new patient data analytics platform SENSIGHT can help double the AIM-listed’s group value according to the house broker Liberum.

SENSIGHT will cost subscribers GBP25,000 per user per annum and initially gives access to a database of 2m patient records.

The depth of the product will rapidly grow, however, believes Liberum, reaching 10mln by year-end, and accelerating thereafter.

() () has agreed a deal with OMNY Health that gives it access to more than 22mln de-identified patient records held by the US firm.

Sensyne North America president, Derek Baird joins Proactive London’s Katie Pilbeam to talk about their partnership which he says has been forged on a mutual belief in the power of real-world data to support breakthrough insights and discoveries.